LitAlert ~~

    <input type="checkbox" id="idlabel" name="boxset" value="data"/>
        <ul class="reflistitem">
            <li class="reftitle">Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.</li>
            <li class="refauth">Mansouri A, McGregor N, Dunn R, Dobbie S, Holmes J, Collins L, Nicum S.</li>
            <li><cite class="refcit">BMJ Open. 2021 Jan 15;11(1):e041463. doi: 10.1136/bmjopen-2020-041463.</cite></li>
        <ul class="pmid">
            <li class="pmidid">PMID: 33452192</li>
            <li class="pmidabs"><a href="" rel="external">PubMed abstract</a></li>
        <ul class="pmid">
            <li><a href="" rel="external">Free Full Text</a></li>

    <input type="checkbox" id="idlabel" name="boxset" value="data"/>
        <ul class="reflistitem">
            <li class="reftitle">Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.</li>
            <li class="refauth">Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, Wu LY, Liu ZL, Gao YN, Wang DB, Lou G, Yang HY, Zhou Q, Kong BH, Huang Y, Chen LP, Li GL, An RF, Wang K, Zhang Y, Yan XJ, Lu X, Lu WG, Hao M, Wang L, Cui H, Chen QH, Abulizi G, Huang XH, Tian XF, Wen H, Zhang C, Hou JM, Mirza MR.</li>
            <li><cite class="refcit">Ann Oncol. 2021 Jan 13:S0923-7534(21)00008-9. doi: 10.1016/j.annonc.2020.12.018. Epub ahead of print.</cite></li>
        <ul class="pmid">
            <li class="pmidid">PMID: 33453391</li>
            <li class="pmidabs"><a href="" rel="external">PubMed abstract</a></li>
        <ul class="pmid">
            <li><a href="" rel="external">Free Full Text</a></li>

LitAlert ~~

    • The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer.
    • Yang C, Arnold AG, Catchings A, Rai V, Stadler ZK, Zhang L.
    • Breast Cancer Res Treat. 2021 Jan 16. doi: 10.1007/s10549-020-06066-7. Epub ahead of print.
    • Morbidity, risk of cancer and mortality in 3,645 HFE mutations carriers.
    • Hagström H, Ndegwa N, Jalmeus M, Ekstedt M, Posserud I, Rorsman F, Nyhlin N, Klintman D, Werner M, Marschall HU, Askling J, Stål P; Swedish Hepatology Study Group (SweHep).
    • Liver Int. 2021 Jan 15. doi: 10.1111/liv.14792. Epub ahead of print.
  • LitAlert ~~

    • Recent advances in the pathology of heritable gastric cancer syndromes.
    • Gullo I, van der Post RS, Carneiro F.
    • Histopathology. 2021 Jan;78(1):125-147. doi: 10.1111/his.14228.
    • Review
    • Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
    • Fransson S, Martinez-Monleon A, Johansson M, Sjöberg RM, Björklund C, Ljungman G, Ek T, Kogner P, Martinsson T.
    • Sci Rep. 2020 Dec 31;10(1):22432. doi: 10.1038/s41598-020-78370-7.
  • LitAlert ~~

    • DNA Methylation in Ovarian Cancer Susceptibility.
    • Reid BM, Fridley BL.
    • Cancers (Basel). 2020 Dec 31;13(1):E108. doi: 10.3390/cancers13010108.
    • Comparative efficacy and safety of PARP inhibitors as maintenance therapy in platinum sensitive recurrent ovarian cancer: a network meta-analysis.
    • Xu Y, Ding L, Tian Y, Bi M, Han N, Wang L.
    • Front Oncol. 2020 Dec 31;10:573801. doi: 10.3389/fonc.2020.573801.
    • Frequency of high-risk hormone receptor-positive breast cancer patients was much higher in Japanese breast cancer patients with germline BRCA1/2 mutations than in sporadic breast cancer patients.
    • Ide Y, Liu L, Miura S, Inuzuka M, Akashi-Tanaka S, Sawada T, Nakamura S.
    • Breast J. 2020 Dec 30. doi: 10.1111/tbj.14150. Epub ahead of print.
    • Commentary
    • Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    • Boerner T, Walch HS, Nguyen B, Iasonos A, Zhou QC, Schultz N, Chui MH, Grisham RN, Tew WP, O'Cearbhaill RE, Aghajanian C, Zivanovic O, Abu-Rustum NR, Gardner GJ, Sonoda Y, Chi DS, Long Roche K.
    • Gynecol Oncol. 2020 Dec 30:S0090-8258(20)34225-6. doi: 10.1016/j.ygyno.2020.12.022. Epub ahead of print.
    • Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    • Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.
    • Jpn J Clin Oncol. 2020 Dec 30:hyaa239. doi: 10.1093/jjco/hyaa239. Epub ahead of print.
    • Surgical Treatment after Neoadjuvant Systemic Therapy in Young Women with Breast Cancer: Results from a Prospective Cohort Study.
    • Kim HJ, Dominici L, Rosenberg SM, Zheng Y, Pak LM, Poorvu PD, Ruddy KJ, Tamimi R, Schapira L, Come SE, Peppercorn J, Borges VF, Warner E, Vardeh H, Collins LC, Gaither R, King TA, Partridge AH.
    • Ann Surg. 2020 Dec 23;Publish Ahead of Print. doi: 10.1097/SLA.0000000000004296. Epub ahead of print.
    • Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review.
    • Tao M, Cheng J, Wu X.
    • Onco Targets Ther. 2020 Dec 18;13:12979-12986. doi: 10.2147/OTT.S281302.
    • Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
    • Kasi A, Al-Jumayli M, Park R, Baranda J, Sun W.
    • J Pancreat Cancer. 2020 Dec 4;6(1):107-115. doi: 10.1089/pancan.2020.0010.
  • LitAlert ~~

    • Performance of breast cancer polygenic risk scores in 760 female CHEK2 germline mutation carriers.
    • Borde J, Ernst C, Wappenschmidt B, Niederacher D, Weber-Lassalle K, Schmidt G, Hauke J, Quante AS, Weber-Lassalle N, Horváth J, Pohl-Rescigno E, Arnold N, Rump A, Gehrig A, Hentschel J, Faust U, Dutrannoy V, Meindl A, Kuzyakova M, Wang-Gohrke S, Weber BHF, Sutter C, Volk AE, Giannakopoulou O, Lee A, Engel C, Schmidt MK, Antoniou AC, Schmutzler RK, Kuchenbaecker K, Hahnen E.
    • J Natl Cancer Inst. 2020 Dec 29. pii: djaa203. doi: 10.1093/jnci/djaa203. [Epub ahead of print]
    • Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
    • Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Coquard I.
    • J Natl Cancer Inst. 2020 Dec 29. pii: djaa193. doi: 10.1093/jnci/djaa193. [Epub ahead of print]
    • Advances in Therapeutic Approaches for Triple Negative Breast Cancer.
    • Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, Lower E, Schwartzberg L, Pegram M.
    • Clin Breast Cancer. 2020 Dec 28:S1526-8209(20)30339-6. doi: 10.1016/j.clbc.2020.12.011. Epub ahead of print.
    • Review
    • Japanese Regulators Approve Lynparza for Ovarian, Prostate, Pancreatic Cancers.
    • [No author given]
    • Precision Oncology News. 2020 Dec 28.
    • Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
    • Hodan R, Kingham K, Cotter K, Folkins AK, Kurian AW, Ford JM, Longacre T.
    • Cancer Med. 2020 Dec 25. doi: 10.1002/cam4.3688. Epub ahead of print.
    • The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.
    • Du ZH, Xia Y, Yang Q, Gao S.
    • Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983289. doi: 10.1177/1533033820983289. [First Published December 24, 2020.]
    • Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
    • Zhan M, Zheng H, Yang Y, He Z, Xu T, Li Q.
    • Cancer Manag Res. 2020 Dec 16;12:12919-12926. doi: 10.2147/CMAR.S283169.
    • Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report.
    • Di Marco M, Carloni R, De Lorenzo S, Mosconi C, Palloni A, Grassi E, Filippini DM, Ricci AD, Rizzo A, Di Federico A, Santini D, Turchetti D, Ricci C, Ingaldi C, Alberici L, Minni F, Golfieri R, Brandi G, Casadei R.
    • World J Gastrointest Oncol. 2020 Dec 15;12(12):1456-1463. doi: 10.4251/wjgo.v12.i12.1456.
  • LitAlert ~~

    • Association between ovarian and breast masses among Chinese women in Chongqing based on ultrasonography screening: A cross-sectional study.
    • Li S, Li H, Tian S, Wu J, Chen YL, Xiao J, Wei JY, Liang XY, Ran L, Kong LQ.
    • Int J Gynaecol Obstet. 2020 Dec 23. doi: 10.1002/ijgo.13568. Epub ahead of print.
    • Calibration of polygenic risk scores is required prior to clinical implementation: results of three common cancers in UKB.
    • Wei J, Shi Z, Na R, Resurreccion WK, Wang CH, Duggan D, Zheng SL, Hulick PJ, Helfand BT, Xu J.
    • J Med Genet. 2020 Dec 21:jmedgenet-2020-107286. doi: 10.1136/jmedgenet-2020-107286. Epub ahead of print.
    • Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.
    • Fortuno C, Lee K, Olivier M, Pesaran T, Mai PL, de Andrade KC, Attardi LD, Crowley S, Gareth Evans D, Feng BJ, Foreman AKM, Frone MN, Huether R, James PA, McGoldrick K, Mester J, Seifert BA, Slavin TP, Witkowski L, Zhang L, Plon SE, Spurdle AB, Savage SA; ClinGen TP53 Variant Curation Expert Panel.
    • Hum Mutat. 2020 Dec 10. doi: 10.1002/humu.24152. Epub ahead of print.
    • Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    • Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, Garcia RL, Lee M, Katz R, Leslie KK, Risques RA, Swisher EM.
    • Gynecol Oncol. 2020 Dec 26:S0090-8258(20)34178-0. doi: 10.1016/j.ygyno.2020.12.007. Epub ahead of print.
  • LitAlert ~~

    • Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    • Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE.
    • Eur J Cancer. 2021 Jan;142:63-82. doi: 10.1016/j.ejca.2020.10.014. Epub 2020 Nov 19.
    • Review
    • Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
    • Ishiyama Y, Shimbo M, Iizuka J, Deshpande G, Tanabe K, Hattori K.
    • PLoS One. 2020 Dec 22;15(12):e0244149. doi: 10.1371/journal.pone.0244149.
    • Hereditary ovarian tumour syndromes: current update on genetics and imaging.
    • Shanbhogue KP, Prasad AS, Ucisik-Keser FE, Katabathina VS, Morani AC.
    • Clin Radiol. 2020 Dec 19:S0009-9260(20)30605-X. doi: 10.1016/j.crad.2020.11.116. Epub ahead of print.
    • Review
    • BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    • Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, Sessa F, Tibiletti MG.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9708. doi: 10.3390/ijms21249708.
  • LitAlert ~~

    • Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    • Singh HM, Bailey P, Hübschmann D, Berger AK, Neoptolemos J, Jäger D, Siveke J, Springfeld C.
    • Genes Chromosomes Cancer. 2020 Dec 20. doi: 10.1002/gcc.22932. Epub ahead of print.
    • Review
    • Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients.
    • Rashid MU, Muhammad N, Ali Khan F, Shehzad U, Naeemi H, Malkani N, Hamann U.
    • Hered Cancer Clin Pract. 2020 Dec 20;18:25. doi: 10.1186/s13053-020-00159-6.
    • Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer.
    • Kumari N, Singh RK, Mishra SK, L R, Mohindra S, Krishnani N.
    • Pathol Res Pract. 2020 Dec 4;217:153309. doi: 10.1016/j.prp.2020.153309. Epub ahead of print.